Trial · NCT00504153
Adverse events43
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 43
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Metabolism and nutrition disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Alkaline phosphatase (ALP) increased | Metabolism and nutrition disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Anemia | Blood and lymphatic system disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 2 | 19 | |
| other | Anorexia | Gastrointestinal disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Aspartate aminotransferase (AST) increased | Metabolism and nutrition disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Blood bilirubin increased | Blood and lymphatic system disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Blood infection | Infections and infestations | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Duodenal stenosis | Gastrointestinal disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Fatigue | General disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 3 | 19 | |
| other | Hemorrhoids | Gastrointestinal disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Hypoglycemia | Metabolism and nutrition disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Hypokalemia | Metabolism and nutrition disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Hyponatremia | Metabolism and nutrition disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | INR increased | Blood and lymphatic system disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Lymphocyte count decreased | Blood and lymphatic system disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Peripheral sensory neuropathy | Nervous system disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| other | Rectal pain | Gastrointestinal disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 1 | 19 | |
| serious | Abdominal pain | General disorders | Dasatinib (Tyrosine Kinase Inhibitor) | 2 | 19 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00504153/events